We are so excited to join Unravel Biosciences in announcing that today the first person has been dosed in the RVL-001 clinical trial for Pitt Hopkins syndrome. This incredible achievement, taking place in Colombia, reflects hours of dedication and an unwavering belief in supporting Pitt Hopkins families all over the world.

Thank you so much to Richard Novak, CEO of Unravel, as he has helped bring this dream to reality for our Pitt Hopkins community. And thank you to our incredible donors & families who have stuck with us through thick and thin.

An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome

With Sincere Gratitude,

Pitt Hopkins Research Foundation